Literature DB >> 35506265

Mental, Neurological, and Somatic Comorbidities and Their Treatment in Persons With Intellectual Disability.

Markus Weih1, Sabine Köhler, Norbert Schöll, Mandy Schulz, Ramona Hering.   

Abstract

BACKGROUND: Persons with intellectual disability (ID) often suffer from significant comorbidities. As data have been lacking until now, the present report is the first one containing outpatient data on the prevalence of ID in Germany, its comorbidities, and outpatient (drug) treatment.
METHODS: This study is based on the nationwide outpatient billing data and drug prescription data of all SHI-insured adults (SHI, statutory health insurance) (age 18-109) who were seen at least once in an outpatient medical practice in 2018. Patients with at least two F70-F79 diagnoses in two quarters were included in the study group (SG) (n = 324 428). A random sample of patients without ID served as the control/comparison group (CG) (n = 648 856). The odds ratios (SG vs. CG) for comorbidities, prescriptions of selected classes of drugs, and involvement of medical specialties were each analyzed by multivariate logistic regression.
RESULTS: The prevalence of ID was 0.55%. ID was found to be associated with a variety of comorbidities. The highest odds ratios [OR] were for infantile cerebral palsy (OR: 121.71; 95% confidence interval: [111.67; 132.67]), autism spectrum disorders (OR: 83.85 [75.54; 93.08]), and developmental disabilities (OR: 61.34 [58.86; 63.94]). The most frequently prescribed drug categories (as classified by the anatomic-therapeutic-chemical (ATC) convention) were psychoactive drugs (antipsychotic, anxiolytic, and hypnotic drugs and sedatives) and antiepileptic drugs (OR: 10.40 [10.27; 10.53] and 9.90 [9.75; 10.05], respectively). Both general practitioners (OR: 2.64 [2.59; 2.69]) and medical specialists were consulted by the SG more frequently than by the CG; the type of specialist most commonly consulted was in the neuropsychiatric field, i.e., a neurologist or psychiatrist (OR: 6.85 [6.77; 6.92]).
CONCLUSION: A diagnosis of ID frequently appears in outpatient billing data. Future analyses should be devoted to the specific care of people with intellectual disability, who constitute an especially multimorbid and vulnerable patient group.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35506265      PMCID: PMC9533706          DOI: 10.3238/arztebl.m2022.0193

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   8.251


  13 in total

1.  A simple method for converting an odds ratio to effect size for use in meta-analysis.

Authors:  S Chinn
Journal:  Stat Med       Date:  2000-11-30       Impact factor: 2.373

Review 2.  Prevalence of intellectual disability: a meta-analysis of population-based studies.

Authors:  Pallab K Maulik; Maya N Mascarenhas; Colin D Mathers; Tarun Dua; Shekhar Saxena
Journal:  Res Dev Disabil       Date:  2011-01-13

3.  Mortality in people with intellectual disabilities in England.

Authors:  G Glover; R Williams; P Heslop; J Oyinlola; J Grey
Journal:  J Intellect Disabil Res       Date:  2016-08-02

Review 4.  Comorbidity of intellectual disability and mental disorder in children and adolescents: a systematic review.

Authors:  Stewart L Einfeld; Louise A Ellis; Eric Emerson
Journal:  J Intellect Dev Disabil       Date:  2011-06

5.  Prevalence of co-occurring psychiatric disorders in adults and adolescents with intellectual disability: A systematic review and meta-analysis.

Authors:  Mario G Mazza; Aurora Rossetti; Giovanna Crespi; Massimo Clerici
Journal:  J Appl Res Intellect Disabil       Date:  2019-08-20

6.  General Measurement Tools for Assessing Mental Health Problems Among Children and Adolescents with an Intellectual Disability: A Systematic Review.

Authors:  Marianne Berg Halvorsen; Sissel Berge Helverschou; Brynhildur Axelsdottir; Per Håkan Brøndbo; Monica Martinussen
Journal:  J Autism Dev Disord       Date:  2022-01-12

7.  Medication use among Australian adults with intellectual disability in primary healthcare settings: a cross-sectional study.

Authors:  Tan N Doan; Nicholas G Lennox; Miriam Taylor-Gomez; Robert S Ware
Journal:  J Intellect Dev Disabil       Date:  2013-04-03

8.  Healthy Ageing and Intellectual Disability study: summary of findings and the protocol for the 10-year follow-up study.

Authors:  Marleen J de Leeuw; Alyt Oppewal; Roy G Elbers; Mireille W E J Knulst; Marco C van Maurik; Marjoleine C van Bruggen; Thessa I M Hilgenkamp; Patrick J E Bindels; Dederieke A M Maes-Festen
Journal:  BMJ Open       Date:  2022-02-22       Impact factor: 2.692

9.  Association of Intellectual Disability With All-Cause and Cause-Specific Mortality in Sweden.

Authors:  Tatja Hirvikoski; Marcus Boman; Magnus Tideman; Paul Lichtenstein; Agnieszka Butwicka
Journal:  JAMA Netw Open       Date:  2021-06-01

10.  UK psychiatrists' experience of withdrawal of antipsychotics prescribed for challenging behaviours in adults with intellectual disabilities and/or autism.

Authors:  Shoumitro Deb; Tom Nancarrow; Bharati Limbu; Rory Sheehan; Mike Wilcock; David Branford; Ken Courtenay; Bhathika Perera; Rohit Shankar
Journal:  BJPsych Open       Date:  2020-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.